IL-21 induces in vivo immune activation of NK cells and CD8 T cells in patients with metastatic melanoma and renal cell carcinoma
Cancer Immunology, Immunotherapy, ISSN: 0340-7004, Vol: 57, Issue: 10, Page: 1439-1449
2008
- 97Citations
- 53Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations97
- Citation Indexes97
- 97
- CrossRef85
- Captures53
- Readers53
- 53
Article Description
Purpose: Human interleukin-21 (IL-21) is a class I cytokine previously reported in clinical studies on immune responsive cancers. Here we report the effects of systemic IL-21 therapy on the immune system in two phase 1 trials with this novel cytokine. Experimental design: Recombinant IL-21 was administered by intravenous bolus injection at dose levels from 1 to 100 μg/kg using two planned treatment regimens: thrice weekly for 6 weeks (3/week); or once daily for five consecutive days followed by nine dose-free days (5 + 9). The following biomarkers were studied in peripheral blood mononuclear cells (PBMC) during treatment: phosphorylation of STAT3, alterations in the composition of leukocyte subsets, ex vivo cytotoxicity, expression of effector molecules in enriched CD8 T cells and CD56 NK cells by quantitative RT-PCR, and gene array profiling of CD8 T cells. Results: Effects of IL-21 were observed at all dose levels. In the 5 + 9 regimen IL-21 induced a dose dependent decrease in circulating NK cells and T cells followed by a return to baseline in resting periods. In both CD8 T cells and CD56 NK cells we found up-regulation of perforin and granzyme B mRNA. In addition, full transcriptome analysis of CD8 T cells displayed changes in several transcripts associated with increased cell cycle progression, cellular motility, and immune activation. Finally, cytotoxicity assays showed that IL-21 enhanced the ability of NK cells to kill sensitive targets ex vivo. Conclusions: IL-21 was biologically active at all dose levels administered with evidence of in vivo NK cell and CD8 T cell activation. © 2008 The Author(s).
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=48149096869&origin=inward; http://dx.doi.org/10.1007/s00262-008-0479-4; http://www.ncbi.nlm.nih.gov/pubmed/18286285; http://link.springer.com/10.1007/s00262-008-0479-4; http://www.springerlink.com/index/10.1007/s00262-008-0479-4; http://www.springerlink.com/index/pdf/10.1007/s00262-008-0479-4; https://dx.doi.org/10.1007/s00262-008-0479-4; https://link.springer.com/article/10.1007/s00262-008-0479-4
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know